2. Signaling Pathways
  3. Cytoskeleton
  4. Collagen

Collagen

Collagen

Collagens are the most abundant proteins in mammals. The collagen family comprises 28 members that contain at least one triple-helical domain. Beyond the existence of 28 collagen types, further diversity occurs in the collagen family because of the existence of several molecular isoforms for the same collagen type (e.g., collagens IV and VI) and of hybrid isoforms comprised of a chains belonging to two different collagen types (type V/XI molecules). Collagens are deposited in the extracellular matrix where most of them form supramolecular assemblies. Four collagens are type II membrane proteins that also exist in a soluble form released from the cell surface by shedding. Collagens play structural roles and contribute to mechanical properties, organization, and shape of tissues. They interact with cells via several receptor families and regulate their proliferation, migration, and differentiation[1].

Collagen Related Products (73):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-NP003
    Collagen, Type II, from bovine snout membrane
    Collagen, Type II, from bovine snout membrane is a type II collagen that can be used for cell culture. This product is enzymatically hydrolyzed collagen peptides.
    Collagen, Type II, from bovine snout membrane
  • HY-Y0775
    1-Bromo-2,5-pyrrolidinedione
    		Ligand 99.74%
    1-Bromo-2,5-pyrrolidinedione is a collagen protein ligand in docking experiments. 1-Bromo-2,5-pyrrolidinedione can be used to study wound healing-related diseases.
    1-Bromo-2,5-pyrrolidinedione
  • HY-108681
    680C91
    		Inhibitor 99.54%
    680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a Ki of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease.
    680C91
  • HY-P0045
    Palmitoyl pentapeptide 4
    		Inducer 99.66%
    Palmitoyl pentapeptide 4 (Matrixyl; Palmitoyl pentapeptide 3; Matrixyl (Palmitoyl Pentapeptide) is a bioactive peptide with anti-ageing effect and has been reported used as a cosmetic ingredient[1]
    Palmitoyl pentapeptide 4
  • HY-P10739
    WYRGRL
    		99.88%
    WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC50 of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis.
    WYRGRL
  • HY-171657
    4'-Acetoxy resveratrol
    		Activator 99.90%
    4'-Acetoxy resveratrol is a Resveratrol (HY-16561) derivative. 4'-Acetoxy resveratrol upregulates gene expression of elastin, collagen types III and IV, superoxide dismutase (SOD), and catalase (CAT), while downregulating interleukins (IL-1A, IL-1R2, IL-6, IL-8) and cyclooxygenase-2 (COX-2) in human skin models. 4'-Acetoxy resveratrol can be used for skin reasearch.
    4'-Acetoxy resveratrol
  • HY-P11623
    4L2-P13D
    		Inhibitor
    4L2-P13D is an IL-11 antagonist with an IC50 of 2.8 μM. 4L2-P13D has a KD of 11 nM for hIL-11. 4L2-P13D exhibits antifibrotic and renoprotective activities. 4L2-P13D can be used in the research of renal fibrosis.
    4L2-P13D
  • HY-P11794A
    Type IV collagen peptide acetate
    		98.18%
    Type IV collagen peptide acetate is a cell-binding ligand peptide derived from type IV collagen. (The sequence is TAGSCLRKFSTM).
    Type IV collagen peptide acetate
  • HY-W014075
    1-Hydroxypyrene
    		Activator 98.78%
    1-Hydroxypyrene, a biomarker of exposure to polycyclic aromatic hydrocarbons (PAHs), is analyzed in urine samples. 1-Hydroxypyrene is the major biomarker of exposure to pyrenes. 1-Hydroxypyrene is the orally active agonist for aryl hydrocarbon receptor (AhR) and can lead to renal fibrosis.
    1-Hydroxypyrene
  • HY-119575
    Tetramethyluric acid
    		Inducer 99.63%
    Tetramethyluric acid (1,3,7,9-Tetramethyluric acid) is an orally active purine alkaloid in Coffea species and Camellia kucha. Tetramethyluric acid exhibits antiviral, and anti-inflammatory activity. Tetramethyluric acid can be used for the research of inflammation disease, and influenza virus infection.
    Tetramethyluric acid
  • HY-107830
    Methyl cholate
    		Inhibitor 99.81%
    Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis.
    Methyl cholate
  • HY-29035
    Dopamine acrylamide
    		98.39%
    Dopamine acrylamide, a polyphenol derivative, can cross-link collagen mainly via noncovalent bonding under acidic-non-oxidized conditions.
    Dopamine acrylamide
  • HY-114557
    NSC 90469
    		Inhibitor 99.41%
    NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity.
    NSC 90469
  • HY-P990294
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
    		Inhibitor
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis.
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
  • HY-172696
    DSPE-PEG2000-WYRGRL
    		Ligand
    DSPE-PEG2000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG2000-WYRGRL can be used for drug delivery.
    DSPE-PEG2000-WYRGRL
  • HY-139589
    Zaloglanstat
    		Inhibitor 98.50%
    Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC50 of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC50 >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH2 to prostaglandin PGE2, thereby inhibiting inflammation-related PGE2 overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE2 release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC50s ??of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases.
    Zaloglanstat
  • HY-131577A
    Neutral protease I
    Neutral protease I (Dispase I) is a rapid, effective, gentle and neutral protease that can separate intact epidermis from the dermis. Neutral protease I can also separate intact epithelial sheets in culture from the substratum. Neutral protease I preserves the viability of the epithelial cells while cleaving the basement membrane zone region. Neutral protease I can also be used to prevent clumping in suspension cultures. Neutral protease I cleaves fibronectin and type IV collagen, but not laminin, type V collagen, serum albumin, or transferrin.
    Neutral protease I
  • HY-N0363
    (+)-Columbianetin
    		Activator 99.04%
    (+)-Columbianetin ((S)-Columbianetin) acts as an inhibitor of JNK/ERK. (+)-Columbianetin inhibits UVA-induced phosphorylation of JNK and ERK, reduces the production of MMP-1, reverses UVA-induced Collagen (HY-NP003) degradation, and alleviates UVA-mediated inhibition of Smad2/3 phosphorylation and translocation. (+)-Columbianetin regulates the AP-1 and ASK1-MAPK signaling pathways, inhibits the production of ROS and blocks sub-G1 cell cycle arrest. (+)-Columbianetin is applicable to research related to skin aging.
    (+)-Columbianetin
  • HY-N2589
    Isosaponarin
    		Inducer 99.59%
    Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin is a P4HA2 enzymatic agonist. Isosaponarin increases collagen synthesis via up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production, promoting skin health and wound healing. Isosaponarin-rich plants exhibit strong antimicrobial, antioxidant, anti-hyaluronidase, antiplatelet, anti-atopic dermatitis, and anti-tumor effects.
    Isosaponarin
  • HY-P10709
    CREKA peptide
    		Inhibitor 99.80%
    CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects.
    CREKA peptide